Clinical Liver Disease
© 2014 The American Association for the Study of Liver Diseases
Recently Published Issues
Current Issue:October 2014
Volume 4, Issue 4
Special Issue: The Pediatric Liver Patient
Volume 4, Issue 3
Special Issue: Liver Disease in Pregnancy
Volume 4, Issue 2
Special Issue: Liver-Lung Syndromes
Volume 4, Issue 1
Special Issue: Drug-Induced Liver Injury (DILI)
Volume 3, Issue 6
Special Issue: Vascular Disorders
New Issue: The Pediatric Liver Patient
|Guest Edited by|
MD, MBBChir, MRCP
The Hospital for Sick Children
Liver Disease in the Survivor with Congenital Heart Disease
Elizabeth B. Rand, MD
The impacts of liver disease in survivors of CHD are diverse - learn about the types, diagnostic modalities and management of liver disease that arises as a direct consequence of CHD.
Liver Disease in the Young Adult with Cystic Fibrosis
Deirdre Kelly, MD
Learn how the rapid development of new diagnostic tests, improved therapy, and especially the success of liver transplantation has changed the outcome for young adults with cystic fibrosis liver disease, many of whom now survive into adolescence and adult life.
Management of Adult Survivors of Biliary Atresia
Simon C. Ling, MB, CHB
Surgical interventions now allow the majority of infants affected by BA to survive into adulthood, leading to a new population of patients - Dr. Simon Ling reviews the clinical status and management priorities for BA patients who survive to adulthood with their native liver.
NAFLD in the Transition From Adolescence to Young Adulthood
Miriam B. Vos, MD, MSPH
Learn about diagnosis, management, and other considerations for liver disease in adolescents after bariatric surgery.
The Adult Survivor with Variceal Bleeding
Juan G. Abraldes, Puneeta Tandon, and Jason Yap
Portal hypertension complicated by variceal bleeding is a rare condition in young adults, but it is a frequent problem faced in transition clinics - read from the experts on what clinicians need to know.
Series on New Treatments for Hepatitis C
Guest Edited by Donald M. Jensen, M.D., F.A.C.P.
HCV Treatment of Special Populations:
HIV Coinfected, Liver Transplant, and Renal Failure
Nadeem Anwar, M.D., and Kenneth E. Sherman, M.D., Ph.D.
With new recommendations regarding birth cohort screening, more and more people will be diagnosed and referred for HCV treatment. Even in the new era of DAA therapy, some populations still require special consideration - learn more from Drs. Anwar and Sherman.
More recent articles on HCV:
HCV Testing and Linkage to Care:
Nancy Reau, M.D.
The limitation to HCV therapy is not treatment efficacy; it's identification of patients and linking them to providers interested in delivering antiviral therapy. Where does the system break down? Dr. Nancy Reau investigates.
New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
For more information related to HCV genotypes, read:
Goossens N, Negro F. Is genotype 3 of hepatitis C virus the new villian? Hepatology. 59:6, 2403–2412, June 2014.
New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.